Skip to content

Viking Therapeutics

US · VKTX #2352 by market cap Listed 2015
24.77 -1.07 -4.14%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:56

Quant vs Street three independent views, side by side

StockVane factor grade
C
Momentum strategy signal
Strong Sell
Analyst consensus
Buy

Signals diverge - worth digging into why.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 16 analysts

Buy
Avg price target 93.53 +277.6%
Price target rangecurrent 24.77
Low34.00
Avg93.53
High125.00
Buy 94% Hold 6% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-10-30 CCORF -- Buy 118.00
2026-10-30 Maxim Group -- Buy 70.00
2026-10-29 UBS -- Buy 94.00
2026-10-29 Piper Sandler -- Buy 90.00
2026-10-29 Maxim Group -- Buy 70.00
2026-10-29 BTIG -- Buy 125.00
2026-10-29 Morgan Stanley -- Buy 95.00
2026-10-29 Stifel -- Buy 95.00
2026-10-29 B. Riley Securities -- Buy 85.00
2026-10-29 H.C. Wainwright -- Buy 102.00
2026-10-29 Oppenheimer -- Buy 120.00
2026-10-28 Cantor Fitzgerald -- Buy 100.00
2026-10-28 Goldman Sachs -- Hold 34.00
2026-10-20 CCORF -- Buy 106.00
2026-10-15 UBS -- Buy 94.00
2026-10-14 CCORF -- Buy 114.00
2026-10-14 H.C. Wainwright -- Buy 102.00
2026-10-07 CCORF -- Buy 114.00
2026-10-07 Truist Financial -- Buy 85.00
2026-10-06 Maxim Group -- Buy 70.00
2026-10-06 Morgan Stanley -- Buy 95.00
2026-10-06 H.C. Wainwright -- Buy 102.00
2026-09-23 CCORF -- Buy 114.00
2026-09-23 Maxim Group -- Buy 70.00
2026-09-23 Truist Financial -- Buy 87.00

Price target trend monthly average, last 3 years

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-10-28 After close ±6.78% +5.91% (in line)
2026/Q2 2026-07-29 After close ±9.38% -0.96% (in line)
2026/Q1 2026-04-29 After close ±7.30% -0.48% (in line)
2025/Q4 2026-02-11 After close ±10.92% +6.80% (in line)
2025/Q3 2025-10-22 After close ±7.93% +7.96% (beat)
2025/Q2 2025-07-23 After close ±11.88% +0.30% (in line)
2025/Q1 2025-04-23 After close ±10.16% -0.50% (in line)
2024/Q4 2025-02-05 After close ±11.71% -6.09% (in line)
2024/Q3 2024-10-23 After close ±9.93% +21.25% (beat)
2024/Q2 2024-07-24 After close ±15.95% +28.31% (beat)
2024/Q1 2024-04-24 After close ±9.78% +5.82% (in line)
2023/Q4 2024-02-07 After close ±20.17% +18.01% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 19:56:05 · For reference only, not investment advice and not tailored to your situation.

Viking Therapeutics discussion 0 comments

Add a comment